Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease.

Aneni EC, Hamer DH, Gill CJ.

Trop Med Int Health. 2013 Mar;18(3):313-27. doi: 10.1111/tmi.12056. Epub 2013 Jan 16. Review.

2.

Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models.

Pino P, Taoufiq Z, Brun M, Tefit M, Franetich JF, Ciceron L, Krishnamoorthy R, Mazier D.

Parasite Immunol. 2006 Dec;28(12):675-80.

3.

Asymptomatic malaria parasitaemia in sickle-cell disease patients: how effective is chemoprophylaxis?

Kotila R, Okesola A, Makanjuola O.

J Vector Borne Dis. 2007 Mar;44(1):52-5.

4.

Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.

Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P, Hodges JS, Ware RE, John CC.

Blood. 2017 Dec 14;130(24):2585-2593. doi: 10.1182/blood-2017-06-788935. Epub 2017 Oct 19.

PMID:
29051184
5.
6.

Advances in sickle cell disease treatment: from drug discovery until the patient monitoring.

dos Santos JL, Lanaro C, Chin CM.

Cardiovasc Hematol Agents Med Chem. 2011 Apr 1;9(2):113-27. Review.

PMID:
21401492
7.

Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.

Okam MM, Ebert BL.

Expert Rev Hematol. 2012 Jun;5(3):303-11. doi: 10.1586/ehm.12.20. Review.

PMID:
22780210
8.

Phytomedicines (medicines derived from plants) for sickle cell disease.

Oniyangi O, Cohall DH.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD004448. doi: 10.1002/14651858.CD004448.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD004448.

PMID:
20927735
9.

Malaria--a shadow over Africa.

Miller LH, Greenwood B.

Science. 2002 Oct 4;298(5591):121-2.

PMID:
12364787
10.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
11.

Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.

Silva-Pinto AC, Angulo IL, Brunetta DM, Neves FI, Bassi SC, Santis GC, Covas DT.

Sao Paulo Med J. 2013;131(4):238-43. doi: 10.1590/1516-3180.2013.1314467.

12.

[Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?].

Mariéthoz S, Pittet B, Loutan L, Humbert J, Montandon D.

Ann Chir Plast Esthet. 1999 Feb;44(1):81-8. Review. French.

PMID:
10188298
13.

Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.

Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F.

Blood. 1997 Apr 1;89(7):2554-9.

14.

The challenge of chloroquine-resistant malaria in sub-Saharan Africa.

Nuwaha F.

Health Policy Plan. 2001 Mar;16(1):1-12. Review.

PMID:
11238424
15.

Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.

Iyamu EW, Cecil R, Parkin L, Woods G, Ohene-Frempong K, Asakura T.

Br J Haematol. 2005 Nov;131(3):389-94.

PMID:
16225659
16.

Pathology of sickle cell disease.

Malowany JI, Butany J.

Semin Diagn Pathol. 2012 Feb;29(1):49-55. Review.

PMID:
22372205
17.

Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.

Covas DT, de Lucena Angulo I, Vianna Bonini Palma P, Zago MA.

Haematologica. 2004 Mar;89(3):273-80.

18.

Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial.

Diop S, Soudré F, Seck M, Guèye YB, Diéye TN, Fall AO, Sall A, Thiam D, Diakhaté L.

Ann Hematol. 2011 Jan;90(1):23-7. doi: 10.1007/s00277-010-1040-z. Epub 2010 Aug 7.

PMID:
20694469
19.

Sickle cell disease clinical phenotypes in children from South-Western, Nigeria.

Adegoke SA, Adeodu OO, Adekile AD.

Niger J Clin Pract. 2015 Jan-Feb;18(1):95-101. doi: 10.4103/1119-3077.146987.

20.

Supplemental Content

Support Center